Inventurus Knowledge Solutions Limited (IKS Health) has released its investor presentation for the quarter and nine months ended December 31, 2025. The company reported a significant year-over-year growth in revenue, with revenue from operations reaching ₹8,150 million (₹815 crore), marking a 24% increase in INR and a 19% increase in USD. EBITDA grew by 40.4% to ₹2,816 million (₹281.6 crore), and Profit After Tax (PAT) saw a 41.4% YoY growth to ₹1,297 million (₹129.7 crore). Adjusted PAT increased by 48.0% to ₹2,154 million (₹215.4 crore). The company highlighted its strategic pillars, including an AI-native agentic platform, integration and optimization following the AQuity acquisition, establishing leadership in features, and a differentiated growth market strategy. IKS Health also emphasized its evolution towards an outcome-oriented company, citing a $3 million NEVA earned in Palomar in the first year. Key deal wins include an expansion of the partnership with VitalMD Group Holding to include ambient solutions, a new partnership with Texas-based StrideCare for revenue cycle management and clinical documentation, expansion of RCM and VBC partnership with a top 5 health system, and a new partnership with a risk-bearing enablement company in the behavioral health sector. IKS Health has been recognized by KLAS Research as the Best in KLAS provider for Virtual Scribe Services for the second time, receiving a score of 91.9. Sachin K. Gupta, Founder & Global CEO, also received the ET Edge Impactful CEO Award. The presentation detailed the company's comprehensive healthcare enablement platform, covering pre-visit, peri-visit, and post-visit services, with a focus on automation. For the nine months ended December 31, 2025, revenue grew by 20.4% to ₹23,361 million (₹2,336.1 crore), and PAT grew by 52.4% to ₹5,156 million (₹515.6 crore). The company also successfully refinanced its existing term loan at more favorable interest rates, resulting in a one-time, non-cash write-off of unamortized debt cost.
